There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and McKesson (MCK – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Eli Lilly & Co, with a price target of $815.00. The company’s shares closed last Monday at $750.77, close to its 52-week high of $800.78.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $856.87, implying a 12.7% upside from current levels. In a report issued on April 3, Erste Group also upgraded the stock to Buy.
See today’s best-performing stocks on TipRanks >>
McKesson (MCK)
Morgan Stanley analyst Erin Wright maintained a Buy rating on McKesson yesterday and set a price target of $548.00. The company’s shares closed last Monday at $522.68, close to its 52-week high of $543.00.
According to TipRanks.com, Wright is a 5-star analyst with an average return of
McKesson has an analyst consensus of Strong Buy, with a price target consensus of $565.64, implying a 7.9% upside from current levels. In a report issued on April 5, Robert W. Baird also maintained a Buy rating on the stock with a $603.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LLY:
- LLY, NVO: Obesity Drugs May Help with Parkinson’s
- Leerink sees ‘marginal’ Q1 downside for Lilly amid supply constraints
- Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
- Roche announces U.S. FDA granted BDD to its Elecsys pTau217 assay
- Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity
